Genomic Health, Inc. (GHDX) CFO Sells $653,110.08 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 11,424 shares of the stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $57.17, for a total transaction of $653,110.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, April 9th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The shares were sold at an average price of $67.61, for a total transaction of $1,014,150.00.
  • On Tuesday, March 12th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The shares were sold at an average price of $75.15, for a total transaction of $1,127,250.00.

Shares of Genomic Health stock traded up $0.15 during mid-day trading on Thursday, hitting $56.60. 12,658 shares of the stock were exchanged, compared to its average volume of 479,936. Genomic Health, Inc. has a twelve month low of $36.94 and a twelve month high of $92.18. The stock has a market capitalization of $2.11 billion, a P/E ratio of 53.99 and a beta of 0.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.67 and a quick ratio of 5.67.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, May 7th. The medical research company reported $0.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.05. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The company had revenue of $108.80 million for the quarter, compared to analysts’ expectations of $106.75 million. During the same period last year, the company earned ($0.11) EPS. The firm’s revenue for the quarter was up 17.5% compared to the same quarter last year. As a group, analysts forecast that Genomic Health, Inc. will post 1.46 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Genomic Health by 166.0% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock worth $55,000 after purchasing an additional 493 shares during the last quarter. Manchester Capital Management LLC acquired a new stake in shares of Genomic Health during the 1st quarter worth about $56,000. Pearl River Capital LLC acquired a new stake in shares of Genomic Health during the 1st quarter worth about $70,000. C M Bidwell & Associates Ltd. acquired a new stake in shares of Genomic Health during the 1st quarter worth about $83,000. Finally, Royce & Associates LP boosted its stake in shares of Genomic Health by 22.8% during the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after purchasing an additional 273 shares during the last quarter. 91.80% of the stock is currently owned by institutional investors.

A number of equities research analysts recently commented on GHDX shares. Zacks Investment Research cut shares of Genomic Health from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. BidaskClub cut shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. Piper Jaffray Companies increased their price objective on shares of Genomic Health to $86.00 and gave the company a “neutral” rating in a research note on Thursday, February 21st. ValuEngine cut shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 5th. Finally, Needham & Company LLC reissued a “strong-buy” rating and issued a $97.00 price objective (up from $86.00) on shares of Genomic Health in a research note on Thursday, February 21st. Ten analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $63.71.

ILLEGAL ACTIVITY NOTICE: This report was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.thestockobserver.com/2019/05/16/genomic-health-inc-ghdx-cfo-sells-653110-08-in-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Further Reading: What are the benefits of a balanced fund?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.